Reaching People, Changing Lives with Innovative Medications
Aurinia is a clinical stage biopharmaceutical company focused on developing and commercializing therapies in disease areas of high unmet medical need. We are currently developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerularsclerosis and minimal change disease (MCD). Additionally, we are advancing voclosporin ophthalmic solution (VOS), a topic formulation, for the treatment of dry eye syndrome (DES).
Our mission is to develop and deliver treatments to people living with debilitating diseases.
Leadership Backed by Extensive Industry Experience
Our highly skilled leadership team has a proven track record of success. Together they possess more than 200 years of combined corporate and industry specific experience. Our strategy leverages the skills and knowledge of our team’s extensive clinical experience in the treatment of renal diseases and autoimmune diseases, such as lupus nephritis.
Contact us to find out more about our dynamic company, and how we are changing the treatment landscape with innovative, next generation products dynamically engineered to improve treatment outcomes.